SCHEMBL1014692

SCHEMBL1014692

CCOC(=O)c1cnc(OC)nc1C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1D P48730 2/20 0.46
FOS P01100 1/20 0.43
JUN P05412 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
HSP90AA1 P07900 1/20 0.42
DPP4 P27487 4/20 0.41
KDM4E B2RXH2 4/20 0.41
HSD17B10 Q99714 1/20 0.41
ALDH1A1 P00352 6/20 0.40
LMNA P02545 2/20 0.40
MAPT P10636 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MAPK1 P28482 1/20 0.40
ATM Q13315 1/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 3/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3821041 0.85 CSNK1D (0.46) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL3825413 0.83 FOS (0.56) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL23094518 0.82 HSP90AA1 (0.59) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL19627329 0.82 CSNK1D (0.45) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL1016549 0.81 KMT2A (0.37) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL1015587 0.80 MEN1 (0.59) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL11597406 0.79 HSP90AA1 (0.47) CSNK1DHSP90AA1DPP4KDM4EALDH1A1
SCHEMBL30830217 0.77 CSNK1D (0.57) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL26984530 0.77 CSNK1D (0.57) CSNK1DFOSJUNNFKB1NFKB2
SCHEMBL3098692 0.77 ALDH1A1 (0.55) CSNK1DHSP90AA1DPP4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2271629-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 AstraZeneca AB (SE) 2011-01-12 EP disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
WO-2009130496-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-29 WO disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 ASTRAZENECA AB (SE) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264401-A1 SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 CYP2S1, HSD11B1, HSD3B1 CSNK1D 127/4885FOS 2690/4885JUN 4258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.